Bromocriptine-QR Therapy and its Impact on the Pro-inflammatory State of Type 2 Diabetes Subjects in Relation to CVD

Sponsored Content 

Bromocriptine-QR (Cycloset) “is a sympatholytic dopamine D2 agonist for the treatment of type 2 diabetes that has demonstrated rapid (within 1 year) substantial reductions in adverse cardiovascular events in this population by as yet incompletely delineated mechanisms.” This study investigated the impact of Cycloset on the pro-inflammatory state of type 2 diabetes subjects as it relates to CVD. The below paper covers the full study in depth.